Two years of postsurgical androgen deprivation therapy resulted in a 10-year metastasis-free survival rate of nearly 80%. The addition of two years of androgen deprivation therapy (ADT) improved ...

Despite a lack of level 1 evidence, metastasis-directed therapy has been increasingly used for the treatment of oligometastatic prostate cancer based on findings from several randomized phase II ...

Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

The second most common cancer among men is prostate cancer, affecting 1 in 8 men. Prostate cancer is treatable, in most cases, when the cancer remains localized to the prostate gland. But if the ...

This meta-analysis of 7 trials provides the highest level of evidence to date supporting MDT for selected patients with oligometastatic prostate cancer. Metastasis-directed therapy (MDT) prolongs ...

Former President Joe Biden's office announced Sunday that he has been diagnosed with an "aggressive" form of prostate cancer, which has spread to his bones. But it said the cancer appears to be ...